Our PDXGEM predictor for cetuximab is able to differentiate the responsive from the nonresponsive even in mCRC patients with wild-type KRAS genes, demonstrating that Integrative usage of PDXGEM along with known companion biomarkers of a targeted therapy has a potential for improving clinical outcomes and thereby the quality of life of a targeted cancer patient population. The gene discussed is KRAS; the disease is cancer.